Institut Pasteur & Austrian Biotech also join the World Zika Vaccine Plan

14/07/2016 - 3 minutes

Themis is a Vienna-based vaccine developer. Together with the Institut Pasteur, it is now planning to use a measles vaccine construct to develop and start Zika vaccine trials within the next 12 months. 

Themis zika vaccine biotech Themis has successfully extended its existing license agreement with Institut Pasteur in Paris, which grants the company a broad access to a well-established virus vaccine vector technology.

The safety and tolerability profile of Themis’ vector was already proven in a Phase I trial when the two partners used the technology platform for the development of a first-in-class Chikungunya vaccine, which will enter into Phase II later this year.

Now the platform will also be applied for the development of a Zika vaccine, a high priority project within Themis’ pipeline.

The technology uses a measles virus vaccine backbone, built from Tehmis’ Themaxyn platform. Since measles vaccines have already been successfully used in well over a billion individuals over the last 30–40 years, this suggests an excellent safety and immunogenicity profile,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following:

Support Us

Become a Member